Comparison Between the 19 and 22 Gauge Needles for Core Tissue Procurement During EUS-guided Procedures

AdventHealth

Status: Withdrawn

Conditions: Pancreatic Cancer

Treatments: Procedure: 19 gauge; Procedure: 22 gauge

Study type: Interventional

Funder types: Other

Identifiers

NCT02366858

510467

Details and patient eligibility

About

The investigators hypothesis is that a 22 gauge needle can yield core tissue, obviating the need to use the 19 gauge needle for core tissue procurement.

Full description

Inclusion Criteria

1. Age under 19 years
2. Pregnant women will be excluded. This will be confirmed by self-report

Exclusion Criteria

1. Age under 19 years
2. Pregnant women will be excluded. This will be confirmed by self-report

Sex: All

Ages: 18 to 89 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients who are referred to Florida Hospital Center for Interventional Endoscopy for a EUS FNA for core biopsy (19 gauge needle biopsy) who have needle dysfunction (This occurs in about 10% of patients)

Exclusion criteria

• Age under 19 years
• Pregnant women will be excluded. This will be confirmed by self-report

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 2 patient groups

19 gauge

Active Comparator group

Description:

Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle.

Treatment:

Procedure: 19 gauge

22 gauge

Active Comparator group

Description:

Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle.

Treatment:

Procedure: 19 gauge

Procedure: 22 gauge